Merck to raise long term revenue forecast on new drugs
Merck plans to raise its long term revenue forecast following strong third quarter results that beat Wall Street estimates. The company is buoyed by clinical trial successes for new cancer treatments as it prepares for patent expirations.
Xurve View
Insights:
Xurve View
MERCK & CO. INC. plans to raise its long-term revenue forecast for new products, driven by clinical trial successes and acquisitions heading into the next decade. The upward revision comes as the drugmaker prepares for the loss of patent protection on its top-selling cancer treatment.
